OptimizeRx Corporation

NasdaqCM:OPRX 주식 보고서

시가총액: US$188.5m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

OptimizeRx 관리

관리 기준 확인 2/4

OptimizeRx's CEO는 Will Febbo, Feb2016 에 임명되었습니다 의 임기는 8.33 년입니다. 총 연간 보상은 $ 2.79M, 16.1% 로 구성됩니다. 16.1% 급여 및 83.9% 보너스(회사 주식 및 옵션 포함). 는 $ 5.48M 가치에 해당하는 회사 주식의 2.77% 직접 소유합니다. 5.48M. 경영진과 이사회의 평균 재임 기간은 각각 3 년과 6.8 년입니다.

주요 정보

Will Febbo

최고 경영자

US$2.8m

총 보상

CEO 급여 비율16.1%
CEO 임기8.3yrs
CEO 소유권2.8%
경영진 평균 재임 기간3yrs
이사회 평균 재임 기간6.8yrs

최근 관리 업데이트

Recent updates

OptimizeRx Corporation's (NASDAQ:OPRX) 36% Jump Shows Its Popularity With Investors

Jan 09
OptimizeRx Corporation's (NASDAQ:OPRX) 36% Jump Shows Its Popularity With Investors

Analyst Forecasts Just Became More Bearish On OptimizeRx Corporation (NASDAQ:OPRX)

Aug 24
Analyst Forecasts Just Became More Bearish On OptimizeRx Corporation (NASDAQ:OPRX)

OptimizeRx Corporation (NASDAQ:OPRX) Shares May Have Slumped 38% But Getting In Cheap Is Still Unlikely

Aug 16
OptimizeRx Corporation (NASDAQ:OPRX) Shares May Have Slumped 38% But Getting In Cheap Is Still Unlikely

Is Now An Opportune Moment To Examine OptimizeRx Corporation (NASDAQ:OPRX)?

May 31
Is Now An Opportune Moment To Examine OptimizeRx Corporation (NASDAQ:OPRX)?

OptimizeRx: A Top Candidate For My Speculative 'Bio Boom' Portfolio

Oct 12

Is Now The Time To Look At Buying OptimizeRx Corporation (NASDAQ:OPRX)?

Sep 23
Is Now The Time To Look At Buying OptimizeRx Corporation (NASDAQ:OPRX)?

OptimizeRx extends reach with Cooler Screens Partnership

Jul 26

OptimizeRx: A Small-Cap Digital Health Technology Gem With Near-Term Inflection In Profitability

Jun 27

The Strong Earnings Posted By OptimizeRx (NASDAQ:OPRX) Are A Good Indication Of The Strength Of The Business

Nov 16
The Strong Earnings Posted By OptimizeRx (NASDAQ:OPRX) Are A Good Indication Of The Strength Of The Business

Why We Think OptimizeRx Corporation's (NASDAQ:OPRX) CEO Compensation Is Not Excessive At All

Aug 13
Why We Think OptimizeRx Corporation's (NASDAQ:OPRX) CEO Compensation Is Not Excessive At All

A Look At The Fair Value Of OptimizeRx Corporation (NASDAQ:OPRX)

Jul 15
A Look At The Fair Value Of OptimizeRx Corporation (NASDAQ:OPRX)

Here's Why We're Not At All Concerned With OptimizeRx's (NASDAQ:OPRX) Cash Burn Situation

Jun 24
Here's Why We're Not At All Concerned With OptimizeRx's (NASDAQ:OPRX) Cash Burn Situation

Investors Will Want OptimizeRx's (NASDAQ:OPRX) Growth In ROCE To Persist

May 10
Investors Will Want OptimizeRx's (NASDAQ:OPRX) Growth In ROCE To Persist

Estimating The Fair Value Of OptimizeRx Corporation (NASDAQ:OPRX)

Mar 29
Estimating The Fair Value Of OptimizeRx Corporation (NASDAQ:OPRX)

Don't Ignore The Fact That This Insider Just Sold Some Shares In OptimizeRx Corporation (NASDAQ:OPRX)

Feb 21
Don't Ignore The Fact That This Insider Just Sold Some Shares In OptimizeRx Corporation (NASDAQ:OPRX)

What Percentage Of OptimizeRx Corporation (NASDAQ:OPRX) Shares Do Insiders Own?

Jan 27
What Percentage Of OptimizeRx Corporation (NASDAQ:OPRX) Shares Do Insiders Own?

CEO 보상 분석

Will Febbo 의 보수는 OptimizeRx 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Mar 31 2024n/an/a

-US$18m

Dec 31 2023US$3mUS$450k

-US$18m

Sep 30 2023n/an/a

-US$14m

Jun 30 2023n/an/a

-US$14m

Mar 31 2023n/an/a

-US$14m

Dec 31 2022US$694kUS$450k

-US$11m

Sep 30 2022n/an/a

-US$10m

Jun 30 2022n/an/a

-US$7m

Mar 31 2022n/an/a

-US$3m

Dec 31 2021US$15mUS$410k

US$378k

Sep 30 2021n/an/a

US$1m

Jun 30 2021n/an/a

US$789k

Mar 31 2021n/an/a

-US$641k

Dec 31 2020US$1mUS$350k

-US$2m

Sep 30 2020n/an/a

-US$6m

Jun 30 2020n/an/a

-US$7m

Mar 31 2020n/an/a

-US$5m

Dec 31 2019US$834kUS$300k

-US$3m

Sep 30 2019n/an/a

-US$1m

Jun 30 2019n/an/a

US$548k

Mar 31 2019n/an/a

US$422k

Dec 31 2018US$923kUS$275k

US$226k

Sep 30 2018n/an/a

US$99k

Jun 30 2018n/an/a

-US$769k

Mar 31 2018n/an/a

-US$1m

Dec 31 2017US$422kUS$250k

-US$2m

보상 대 시장: Will 의 총 보상 ($USD 2.79M )은 US 시장( $USD 1.62M ).

보상과 수익: 회사가 수익성이 없는 동안 Will 의 보상이 증가했습니다.

CEO

Will Febbo (55 yo)

8.3yrs

테뉴어

US$2,789,528

보상

Mr. William J. Febbo, also known as Will, is a Director at LifeMD, Inc. since June 2023. He serves as an Independent Director at Augmedix, Inc. since March 28, 2022. He served as an Independent Director of...

리더십 팀

이름위치테뉴어보상소유권
William Febbo
CEO & Director8.3yrsUS$2.79m2.77%
$ 5.2m
Stephen Silvestro
President1.4yrsUS$970.36k0.40%
$ 751.8k
Edward Stelmakh
CFO & COO2.7yrsUS$929.73k0.11%
$ 198.1k
Andrew D'Silva
Senior Vice President of Corporate Finance2.8yrs데이터 없음데이터 없음
Marion Odence-Ford
General Counsel & Chief Compliance Officer3.3yrsUS$2.51m0.078%
$ 146.9k
Maira Alejandra
Media Relations Managerno data데이터 없음데이터 없음
Sheryl Kearney
Human Resources Manager4.5yrs데이터 없음데이터 없음
Terence Hamilton
Senior Vice President of Pharma4.3yrsUS$511.63k데이터 없음
Doug Besch
Chief Product Officer1.7yrs데이터 없음0.021%
$ 39.7k
Theresa Greco
Chief Commercial Officerless than a year데이터 없음0.10%
$ 191.1k
Heather Favazza
Controller5.7yrs데이터 없음데이터 없음

3.0yrs

평균 재임 기간

56.5yo

평균 연령

경험이 풍부한 관리: OPRX 의 관리팀은 경험 ( 3 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름위치테뉴어보상소유권
William Febbo
CEO & Director8.1yrsUS$2.79m2.77%
$ 5.2m
Patrick Spangler
Independent Director6.3yrsUS$215.01k0.18%
$ 332.1k
Catherine Klema
Independent Directorless than a year데이터 없음데이터 없음
Gus Halas
Director9.8yrsUS$249.01k0.44%
$ 835.2k
Gregory Wasson
Independent Director3.9yrsUS$195.01k0.19%
$ 351.2k
Ellen Vos
Independent Chairperson of the Board8.8yrsUS$208.01k0.27%
$ 510.7k
Jack Pinney
Head of Medical Advisory Board6.3yrsUS$112.91k데이터 없음
James Lang
Independent Director7.4yrsUS$204.01k0.30%
$ 565.1k

6.8yrs

평균 재임 기간

66.5yo

평균 연령

경험이 풍부한 이사회: OPRX 의 이사회는 경험(평균 재직 기간 6.8 년)으로 간주됩니다.